Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm’s label expansion in rare form of obesity
Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a

